(Bloomberg) -- Drug development is a risky business, with an estimated 90 percent of compounds that enter clinical trials ultimately failing to reach the market.
Governments, academic groups and drugmakers have been seeking to improve those odds through partnerships that bring together the expertise of scientists in a broad array of fields, from biology to genomics. The goal is to identify biological targets for drugs and weed out failures before they reach human testing.
Register or login for access to this item and much more
All Information Management content is archived after seven days.
Community members receive:
- All recent and archived articles
- Conference offers and updates
- A full menu of enewsletter options
- Web seminars, white papers, ebooks
Already have an account? Log In
Don't have an account? Register for Free Unlimited Access